Central Microscopy Microscopy remains central to both laboratory and clinical cancer research. The principal goal of the Central Microscopy Research Facility (CMRF) is to provide services and instruction to HCCC investigators interested in using microscopy technology for cancer research. The CMRF provides technical assistance for labor intensive techniques and ready access to highly specialized and expensive equipment. It supports cancer research being done by members of all 6 research programs. Specific services available to HCCC investigators include expertise related to tissue preparation, fixation and staining for: 1) Light microscopy 2) Histochemical and fluorescence microscopy 3) Confocal, multiphoton and electron microscopy 4) In situ hybridization 5) Elemental and chemical characterization 5) In vivo small animal imaging using the IVIS imaging system The CMRF provides consultation and assistance to HCCC investigators in the development and application of new and specialized morphological methods relevant to cancer research. In 2009, 80 HCCC members with peer reviewed funding utilized the CMRF.

Public Health Relevance

Light, fluorescence, confocal, and electron microscopy are central tools for many aspects of laboratory and clinical cancer research. The CMRF provides a comprehensive, state-of-the-art array of microscopy instrumentation and techniques to HCCC members conducting cancer research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA086862-13
Application #
8466221
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-04-01
Budget End
2014-03-31
Support Year
13
Fiscal Year
2013
Total Cost
$82,596
Indirect Cost
$31,206
Name
University of Iowa
Department
Type
DUNS #
062761671
City
Iowa City
State
IA
Country
United States
Zip Code
52242
Sarkar, Koustav; Han, Seong-Su; Wen, Kuo-Kuang et al. (2018) R-loops cause genomic instability in T helper lymphocytes from patients with Wiskott-Aldrich syndrome. J Allergy Clin Immunol 142:219-234
Grogan, Nicole; Swami, Umang; Bossler, Aaron D et al. (2018) Toxicities with targeted therapies after immunotherapy in metastatic melanoma. Melanoma Res 28:600-604
Meng, Xiangbing; Bi, Jianling; Li, Yujun et al. (2018) AZD1775 Increases Sensitivity to Olaparib and Gemcitabine in Cancer Cells with p53 Mutations. Cancers (Basel) 10:
Klingelhutz, Aloysius J; Gourronc, Francoise A; Chaly, Anna et al. (2018) Scaffold-free generation of uniform adipose spheroids for metabolism research and drug discovery. Sci Rep 8:523
Tracy, Sean I; Habermann, Thomas M; Feldman, Andrew L et al. (2018) Outcomes among North American patients with diffuse large B-cell lymphoma are independent of tumor Epstein-Barr virus positivity or immunosuppression. Haematologica 103:297-303
Zhu, Yueming; Dean, Angela Elizabeth; Horikoshi, Nobuo et al. (2018) Emerging evidence for targeting mitochondrial metabolic dysfunction in cancer therapy. J Clin Invest 128:3682-3691
Ebeid, Kareem; Meng, Xiangbing; Thiel, Kristina W et al. (2018) Synthetically lethal nanoparticles for treatment of endometrial cancer. Nat Nanotechnol 13:72-81
Do, Anh-Vu; Geary, Sean M; Seol, Dongrim et al. (2018) Combining ultrasound and intratumoral administration of doxorubicin-loaded microspheres to enhance tumor cell killing. Int J Pharm 539:139-146
Gold, Joshua M; Stuart, Jillian O'Rourke; Thiem, Kelsey C et al. (2018) The unintended impact of smoking-risk information on concerns about radon: A randomized controlled trial. Health Psychol 37:1123-1133
Gourronc, Francoise A; Robertson, Larry W; Klingelhutz, Aloysius J (2018) A delayed proinflammatory response of human preadipocytes to PCB126 is dependent on the aryl hydrocarbon receptor. Environ Sci Pollut Res Int 25:16481-16492

Showing the most recent 10 out of 1080 publications